Optomed Oyj — AGM Information 2021

Apr 28, 2021

Decisions of the Annual General Meeting and Board of Directors

Decisions of the Annual General Meeting and Board of Directors

Optomed Plc         Stock Exchange Release    28 April 2021 at 15:00, Helsinki

Decisions of the Annual General Meeting and Board of Directors

Decisions of the Annual General Meeting:

The Annual General Meeting held on 28 April 2021 adopted the financial
statements for the financial period ended on 31 December 2020 and the
remuneration report for governing bodies and discharged the members of the Board
of Directors and the CEO from liability for the financial period ended on 31
December 2020.

The Annual General Meeting resolved in accordance with the proposal of the Board
of Directors that no dividend will be paid for the year 2020.

The number of members of the Board of Directors was confirmed as five:

· Seppo Mäkinen, Petri Salonen, Reijo Tauriainen and Anna Tenstam were re
-elected as members of the Board
· Xisi Guo was elected as a new member of the Board.

The Annual General Meeting confirmed the annual Board remuneration as follows:

· Chairman of the Board EUR 36,000
· members of the Board EUR 18,000.

In addition, a meeting fee in the amount of EUR 500 is paid to the Chairman of
the Audit Committee for each Audit Committee meeting. 40 percent of the Board
remuneration is paid in Optomed shares and 60 percent in cash. The remuneration
will be paid once a year in August, after Optomed’s H1 report has been
announced.

The Annual General Meeting decided to elect KPMG Oy Ab, a firm of authorized
public accountants, as the Company’s auditor. KPMG Oy Ab has informed the
Company that Authorized Public Accountant Tapio Raappana will continue as the
auditor with principal responsibility. Auditor’s remuneration will be paid in
accordance with an invoice approved by the Company.

The General Meeting approved the authorization for the Board of Directors to
repurchase Optomed’s own shares and to accept them as pledge. Altogether no more
than 1,400,314 shares may be repurchased or accepted as pledge. The
authorization will be valid until the earlier of the end of the next Annual
General Meeting or 18 months from the resolution of the Annual General Meeting.

The General Meeting authorized the Board of Directors to decide on the issuance
of shares as well as the issuance of option rights and other special rights
entitling to shares referred to in Chapter 10, Section 1 of the Finnish
Companies Act. The number of shares to be issued based on this authorization may
not exceed 1,400,314. The Board of Directors is authorized to resolve on all
terms and conditions of the issuance of shares and special rights entitling to
shares, including the right to derogate from the pre-emptive right of the
shareholders. The authorization will be valid until the earlier of the end of
the next Annual General Meeting or 18 months from the resolution of the Annual
General Meeting.

Decisions of the Board of Directors:

At its meeting held after the Annual General Meeting, the Board of Directors
elected from among its members Petri Salonen as its Chairman. The committee
members were elected as follows:

Audit Committee:

· Reijo Tauriainen (Chairman)
· Seppo Mäkinen
· Anna Tenstam

Remuneration Committee:

· Seppo Mäkinen (Chairman)
· Reijo Tauriainen
· Anna Tenstam

Optomed Plc

Further enquiries

Sakari Knuutti, CLO, Optomed Plc, sakari.knuutti@optomed.com

Optomed in Brief

Optomed is a Finnish medical technology company and one of the leading providers
of handheld fundus cameras. Optomed combines handheld screening devices with
software and artificial intelligence with the aim to transform the diagnostic
process of blinding eye-diseases such as rapidly increasing diabetic
retinopathy. In its business Optomed focuses on eye-screening devices and
software solutions related R&D in Finland and sales through different channels
in over 60 countries. The company has an extensive portfolio of 56 international
patents protecting the technology.